Neil M. Barth

1.8k total citations
41 papers, 953 citations indexed

About

Neil M. Barth is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Neil M. Barth has authored 41 papers receiving a total of 953 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 23 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Neil M. Barth's work include Immunotherapy and Immune Responses (22 papers), Cancer Immunotherapy and Biomarkers (20 papers) and CAR-T cell therapy research (17 papers). Neil M. Barth is often cited by papers focused on Immunotherapy and Immune Responses (22 papers), Cancer Immunotherapy and Biomarkers (20 papers) and CAR-T cell therapy research (17 papers). Neil M. Barth collaborates with scholars based in United States, Australia and Italy. Neil M. Barth's co-authors include Robert O. Dillman, Linda D. Beutel, Shankar K. Nayak, Carol DePriest, Cristina de Leon, Robert Birch, Louis A. VanderMolen, R. K. Oldham, Senthamil R. Selvan and W. H. West and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Neil M. Barth

40 papers receiving 906 citations

Peers

Countries citing papers authored by Neil M. Barth

Since Specialization

Citations

This map shows the geographic impact of Neil M. Barth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil M. Barth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil M. Barth more than expected).

Fields of papers citing papers by Neil M. Barth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil M. Barth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil M. Barth. The network helps show where Neil M. Barth may publish in the future.

Co-authorship network of co-authors of Neil M. Barth

This figure shows the co-authorship network connecting the top 25 collaborators of Neil M. Barth. A scholar is included among the top collaborators of Neil M. Barth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil M. Barth. Neil M. Barth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning 2017 ·Annals of the American Thoracic Society ·Daniel G. Pankratz, Yoonha Choi, (unknown), Grazyna Fedorowicz, (unknown), Thomas V. Colby, Jeffrey L. Myers, David A. Lynch, Kevin K. Brown, Kevin R. Flaherty, Mark P. Steele, Steve D. Groshong, Ganesh Raghu, Neil M. Barth, P. Sean Walsh, Jing Huang, Giulia C. Kennedy, Fernando J. Martínez	53
2	Analytical performance of Envisia: a genomic classifier for usual interstitial pneumonia 2017 ·BMC Pulmonary Medicine ·Yoonha Choi, Jiayi Lu, Zhanzhi Hu, Daniel G. Pankratz, (unknown), Manqiu Cao, (unknown), (unknown), Grazyna Fedorowicz, (unknown), (unknown), Edward Tom, Joshua Babiarz, (unknown), Neil M. Barth, P. Sean Walsh, Giulia C. Kennedy, Jing Huang	19
3	Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment 2015 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Edward F. McClay, Neil M. Barth, Thomas Amatruda, Lee S. Schwartzberg, (unknown), Cristina de Leon, (unknown), Carol DePriest	18
4	Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma? 2012 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, (unknown), Stephanie E. McClure	21
5	Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer? 2011 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, (unknown), (unknown), Stephanie E. McClure	8
6	A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer 2011 ·American Journal of Otolaryngology ·Brian Kim, Robert O. Dillman, Peter Chen, (unknown), (unknown), Neil M. Barth, (unknown), Louis A. VanderMolen, Minh Nguyen, (unknown), (unknown), Marianne Plunkett, (unknown)	2
7	Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Antitumor Vaccines in Patients with Metastatic Melanoma: Final Report 2009 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Senthamil R. Selvan, Patric M. Schiltz, Edward F. McClay, Neil M. Barth, Carol DePriest, Cristina de Leon, (unknown), Andrew N. Cornforth, (unknown)	56
8	Patient-Specific Vaccines Derived from Autologous Tumor Cell Lines as Active Specific Immunotherapy: Results of Exploratory Phase I/II Trials in Patients with Metastatic Melanoma 2007 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Carol DePriest, (unknown), Neil M. Barth, Lee S. Schwartzberg, Linda D. Beutel, Patric M. Schiltz, Shankar K. Nayak	29
9	Autologous Tumor Cell Line–Derived Vaccine for Patient-Specific Treatment of Advanced Renal Cell Carcinoma 2004 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, (unknown), Linda D. Beutel, Cristina de Leon, Carol DePriest, Shankar K. Nayak	13
10	Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis 2004 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Senthamil R. Selvan, Patric M. Schiltz, (unknown), (unknown), Carol DePriest, Edward F. McClay, Neil M. Barth, (unknown), Cristina de Leon, Linda D. Beutel	34
11	Autologous Tumor Cell Line–Derived Vaccine for Patient-Specific Treatment of Advanced Renal Cell Carcinoma 2004 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, (unknown), Linda D. Beutel, Cristina de Leon, Carol DePriest, Shankar K. Nayak	16
12	Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis 2004 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Senthamil R. Selvan, Patric M. Schiltz, (unknown), (unknown), Carol DePriest, Edward F. McClay, Neil M. Barth, (unknown), Cristina de Leon, Linda D. Beutel	16
13	Tumor-Infiltrating Lymphocytes and Interleukin-2: Dose and Schedules of Administration in the Treatment of Metastatic Cancer 2004 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Patric M. Schiltz, (unknown), Neil M. Barth, Linda D. Beutel, Cristina de Leon, (unknown), Shankar K. Nayak	26
14	Phase I/II Trial of Autologous Tumor Cell Line–Derived Vaccines for Recurrent or Metastatic Sarcomas 2004 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Neil M. Barth, Senthamil R. Selvan, Linda D. Beutel, Cristina de Leon, Carol DePriest, (unknown), Shankar K. Nayak	31
15	Phase I/II Trial of Autologous Tumor Cell Line–Derived Vaccines for Recurrent or Metastatic Sarcomas 2004 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Neil M. Barth, Senthamil R. Selvan, Linda D. Beutel, Cristina de Leon, Carol DePriest, (unknown), Shankar K. Nayak	31
16	Irradiated Cells from Autologous Tumor Cell Lines as Patient-Specific Vaccine Therapy in 125 Patients with Metastatic Cancer: Induction of Delayed-Type Hypersensitivity to Autologous Tumor is Associated with Improved Survival 2002 ·Cancer Biotherapy and Radiopharmaceuticals ·Robert O. Dillman, Linda D. Beutel, Neil M. Barth, Cristina de Leon, (unknown), Carol DePriest, Shankar K. Nayak	37
17	Interferon-α2a and 13-cis-retinoic acid with radiationtreatment for high-grade glioma 2001 ·Neuro-Oncology ·Robert O. Dillman, William M. Shea, (unknown), (unknown), Neil M. Barth, (unknown), (unknown), (unknown), Carol DePriest	23
18	Interferon-α and chemohormonal therapy for patients with advanced melanoma 1998 ·Cancer ·James J. Stark, Robert O. Dillman, Richard S. Schulof, Michael C. Wiemann, Neil M. Barth, (unknown), Gamini S. Soori	20
19	Long-term Survival after Continuous Infusion Interleukin-2 1997 ·Cancer Biotherapy and Radiopharmaceuticals ·R O Dillman, (unknown), Neil M. Barth, Robert K. Oldham, Michael C. Wiemann	18
20	Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. 1991 ·Journal of Clinical Oncology ·Robert O. Dillman, R. K. Oldham, Kurt W. Tauer, Douglas Orr, Neil M. Barth, George R. Blumenschein, (unknown), Robert Birch, W. H. West	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact